ClinicalTrials.gg

Program

letetresgene autoleucel

Also written as “Letetresgene autoleucel”, “letetresgene autoleucel (GSK3377794)” and “Letetresgene autoleucel (Lete-Cel (GSK3377794))”.

Its studies are mostly in Neoplasms · Liposarcoma, Myxoid · Multiple Myeloma · Carcinoma, Non-Small-Cell Lung · Sarcoma, Synovial, led by 3 companies.

Furthest: phase 2, since Dec 12, 20167 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKline40 open or runningphase 2since Dec 12, 2016Oct 26, 2015none ahead
USWM CT21 open or runningphase 2since May 10, 2019May 10, 2019none ahead
USWM, LLC (dba US WorldMeds)10 open or runningphase 2since Aug 7, 2023Aug 7, 2023none ahead

Also a collaborator on its studies: Merck.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 26, 2015First study: phase 1 study in NeoplasmsNew to GlaxoSmithKlineGlaxoSmithKline · NCT02588612 · 10 enrolled · United States
  2. Dec 12, 2016Phase 2 study in NeoplasmsGlaxoSmithKline · NCT02992743 · 23 enrolled · United States
  3. May 24, 2017Phase 1 study in NeoplasmsGlaxoSmithKline · NCT03168438 · 6 enrolled · United States
  4. Oct 4, 2018Phase 2 study in NeoplasmsGlaxoSmithKline · NCT03697824
  5. May 10, 2019USWM CT’s first study: phase 2 study in NeoplasmsNew to USWM CTUSWM CT · NCT03967223 · 103 enrolled · United States, Canada, France and more
  6. Aug 7, 2023USWM, LLC (dba US WorldMeds)’s first study: phase 2 study in NeoplasmsNew to USWM, LLC (dba US WorldMeds)USWM, LLC (dba US WorldMeds) · NCT05993299 · 7 enrolled · United States, Canada, France and more
  7. Nov 21, 2024Phase 2 study in NeoplasmsUSWM CT · NCT06703346 · 82 enrolled · United States, Canada, France and more

TargetBeta

“Human autologous T-lymphocytes transduced with a lentiviral vector encoding a T-cell receptor (TCR) specific for the cancer-testis antigens (CTAs) NY-ESO-1 and L antigen family member 1 (LAGE-1; Cancer/Testis Antigen 2; CTAG2; CT2), ”NCIt, by rule

Studies

All 7 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06703346Neoplasms · United States, Canada, France and more2CompletedUSWM CTMar 1, 202482
NCT05993299Neoplasms · United States, Canada, France and more2CompletedUSWM, LLC (dba US WorldMeds)Oct 12, 20227
NCT03967223Neoplasms · United States, Canada, France and more2Active, not recruitingUSWM CTMar 1, 2024103
NCT03697824Neoplasms2WithdrawnGlaxoSmithKlineJul 18, 20220
NCT03168438Neoplasms · United States1TerminatedGlaxoSmithKlineJul 13, 20206
NCT02992743Neoplasms · United States2CompletedGlaxoSmithKlineNov 1, 202123
NCT02588612Neoplasms · United States1CompletedGlaxoSmithKlineAug 10, 202010

How it is read

Names in the registry

  • “Letetresgene autoleucel”, 2 entries
  • “letetresgene autoleucel (GSK3377794)”, 2 entries
  • “Letetresgene autoleucel (Lete-Cel (GSK3377794))”, 1 entry
  • “Letetresgene autoleucel (lete-cel, GSK3377794)”, 1 entry
  • “Letetresgene autoleucel with pembrolizumab”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.